XENGLU MET 12.5 1000MG TAB 28s

Xenglu‑Met 12.5 mg / 1000 mg tablets (strip of 28s), containing Empagliflozin 12.5 mg + Metformin HCl 1000 mg, manufactured by Hilton Pharmaceuticals Pvt. Ltd., Pakistan

 What Is It & How It Works

• Empagliflozin (SGLT-2 inhibitor): helps lower blood sugar by blocking glucose reabsorption in the kidneys, increasing urinary glucose excretion Metformin (biguanide): reduces hepatic glucose production, improves insulin sensitivity, and delays intestinal glucose absorption Indication: Used as an adjunct to diet and exercise to manage type 2 diabetes mellitus when either agent alone or other combinations are insufficient

Benefits & Therapeutic EffectsEffective glycemic control: Covers multiple metabolic pathways to reduce HbA1c, fasting, and postprandial glucose levels 

• Weight benefit: Empagliflozin may promote modest weight loss via caloric excretion in urine Cardiorenal protection: Empagliflozin has demonstrated reduction in heart failure hospitalizations and kidney disease progression in high-risk patients Convenience: Combines two classes in one daily pill simplifies treatment adherence and lowers pill burden 

 Dosage & Administration

• Typical starting dose: 1 tablet once daily with meals 

• Titration: May increase to 2 tablets per day if needed, provided total metformin ≤ 2000 mg/day and empagliflozin ≤ 25 mg/day Formulation: Immediate Release (IR) vs. Extended Release (XR) versions available; follow your prescription accordingly 

Common Side Effects

• GI upset from metformin: Diarrhea, nausea, flatulence, abdominal pain, loss of appetite, indigestion, headache, fatigueGenitourinary effects from empagliflozin: Urinary tract infections, female genital mycotic infections (yeast), increased urination 

• Hypoglycemia: Rare when used alone, but increased risk when combined with insulin or secretagogues